$0.50 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter

Brokerages forecast that Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) will report earnings per share of $0.50 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Halozyme Therapeutics’ earnings. The highest EPS estimate is $0.52 and the lowest is $0.48. Halozyme Therapeutics posted earnings per share of $0.66 during the same quarter last year, which suggests a negative year over year growth rate of 24.2%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Halozyme Therapeutics will report full year earnings of $2.21 per share for the current year, with EPS estimates ranging from $2.18 to $2.23. For the next fiscal year, analysts forecast that the company will report earnings of $3.26 per share, with EPS estimates ranging from $3.16 to $3.36. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.02). Halozyme Therapeutics had a net margin of 92.23% and a return on equity of 132.71%. The firm had revenue of $117.30 million for the quarter, compared to analyst estimates of $128.25 million. During the same quarter in the prior year, the firm posted $0.34 EPS. The firm’s revenue for the quarter was up 31.8% compared to the same quarter last year.

Several research firms recently issued reports on HALO. StockNews.com downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. SVB Leerink initiated coverage on Halozyme Therapeutics in a research note on Monday. They issued an “outperform” rating and a $52.00 price objective on the stock. Piper Sandler reduced their target price on Halozyme Therapeutics from $43.00 to $42.00 in a report on Wednesday, February 23rd. Finally, Zacks Investment Research raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating and set a $37.00 price objective for the company in a report on Monday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $48.50.

Several hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $42,068,000. Allspring Global Investments Holdings LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth $35,784,000. Snyder Capital Management L P grew its stake in shares of Halozyme Therapeutics by 18.6% during the fourth quarter. Snyder Capital Management L P now owns 4,064,779 shares of the biopharmaceutical company’s stock valued at $163,445,000 after acquiring an additional 637,303 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Halozyme Therapeutics by 21.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,765,247 shares of the biopharmaceutical company’s stock worth $111,191,000 after purchasing an additional 497,705 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 62.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,183,621 shares of the biopharmaceutical company’s stock worth $48,149,000 after acquiring an additional 456,977 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Shares of Halozyme Therapeutics stock opened at $44.33 on Tuesday. The company has a market capitalization of $6.12 billion, a price-to-earnings ratio of 14.83 and a beta of 1.24. The company has a quick ratio of 8.42, a current ratio of 8.85 and a debt-to-equity ratio of 3.03. Halozyme Therapeutics has a 12-month low of $31.36 and a 12-month high of $46.62. The firm’s 50-day moving average price is $40.80 and its two-hundred day moving average price is $37.45.

Halozyme Therapeutics Company Profile (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Stories

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.